Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Day One Biopharmaceuticals stock
Learn how to easily invest in Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals is a biotechnology business based in the US. Day One Biopharmaceuticals shares (DAWN) are listed on the NASDAQ and all prices are listed in US Dollars. Day One Biopharmaceuticals employs 125 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Day One Biopharmaceuticals stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – DAWN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Day One Biopharmaceuticals stock price (NASDAQ: DAWN)Use our graph to track the performance of DAWN stocks over time.
Day One Biopharmaceuticals shares at a glance
|Latest market close||$12.06|
|52-week range||$5.44 - $28.35|
|50-day moving average||$14.13|
|200-day moving average||$19.42|
|Wall St. target price||$39.56|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.17|
Buy Day One Biopharmaceuticals stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Day One Biopharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Day One Biopharmaceuticals price performance over time
Historical closes compared with the close of $12.06 from 2023-05-25
|1 week (2023-05-19)||-9.73%|
|1 month (2023-04-27)||-0.33%|
|3 months (2023-02-27)||-34.24%|
|6 months (2022-11-25)||-43.67%|
|1 year (2022-05-27)||110.84%|
|2 years (2021-05-27)||-53.42%|
|3 years (2020-05-27)||4,724.00%|
|5 years (2018-05-23)||N/A|
Day One Biopharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-34.88%|
|Return on equity TTM||-56.01%|
|Market capitalisation||$982.9 million|
TTM: trailing 12 months
Day One Biopharmaceuticals share dividends
We're not expecting Day One Biopharmaceuticals to pay a dividend over the next 12 months.
Day One Biopharmaceuticals overview
Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. .
Day One Biopharmaceuticals in the news
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
Frequently asked questionsWhat percentage of Day One Biopharmaceuticals is owned by insiders or institutions?
Currently 29.284% of Day One Biopharmaceuticals shares are held by insiders and 82.303% by institutions. How many people work for Day One Biopharmaceuticals?
Latest data suggests 125 work at Day One Biopharmaceuticals. When does the fiscal year end for Day One Biopharmaceuticals?
Day One Biopharmaceuticals's fiscal year ends in December. Where is Day One Biopharmaceuticals based?
Day One Biopharmaceuticals's address is: 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Day One Biopharmaceuticals's ISIN number?
Day One Biopharmaceuticals's international securities identification number is: US23954D1090
More guides on Finder
JP Morgan Personal Advisors review 2023
Access remote advice, planning and portfolio management from this established financial services company.
How to buy Energy Transfer Equity stock
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
How to buy Uranium Energy stock
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
How to buy Gold Royalty stock
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Best online brokers & platforms to buy gold stocks in May 2023
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
How to buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Ask an Expert